New pill could help lung damage after transplant
NCT ID NCT02669251
First seen Oct 31, 2025 · Last updated Apr 25, 2026 · Updated 16 times
Summary
This study tests a new oral drug called alvelestat for people who develop a serious lung condition (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug aims to block a harmful enzyme that may damage the lungs. About 14 adults with chronic graft-versus-host disease and lung problems will take the drug for up to a year to see if it is safe and improves breathing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.